Duncan Bridgeman
|
Friday 14th November 2003 |
Text too small? |
However, a policy change in accounting for foreign exchange hedges made comparisons with the same period a year ago misleading.
F&P Healthcare shares traded early yesterday at $12.05, down 20c since the interim profit announcement on Wednesday.
While net profit fell to $25.2 million, revenue growth from new products climbed 27% in US dollar terms, pushing operating revenue up 3.8% to a record $104.9 million.
The company is forecasting full year revenue of between $US120 million ($193.5 million) and $US125 million.
ABN Amro said in a research note it was reviewing its target price of $13.14 and its add recommendation on the stock. The broking house noted that the company's new obstructive sleep apnoea (OSA) flow generators would be fully established in the second half of the current financial year while its new mask products should continue to increase consumables market sha
No comments yet
Devon Funds Morning Note - 12 March 2026
TCM - Financial Model
BRM - Scheme of Arrangement Update - NZ Commerce Commission
Devon Funds Morning Note - 11 March 2026
BGP - Full Year Results to 25 January 2026
BRM - Scheme of Arrangement Update - NZ Commerce Commission
The oil shock
Air New Zealand suspends FY2026 guidance
March 10th Morning Report
FSF - Mainland Group sale unconditional